Aquestive(AQST) - 2024 Q3 - Quarterly Results

Exhibit 99.1 Aquestive Therapeutics Reports Third Quarter 2024 Financial Results and Provides Business Update • Anaphylm™ (epinephrine) Sublingual Film pre-NDA meeting scheduled for fourth quarter 2024 • AQST-108 (epinephrine) Topical Gel pre-IND meeting scheduled for fourth quarter 2024 • Libervant® (diazepam) Buccal Film for patients aged 2-5 available through retail distribution channels • Finished third quarter 2024 with approximately $78 million of cash and reaffirms cash runway into 2026 • To host inv ...